GSK is shifting to specialty growth (HIV, oncology, asthma) with key launches and a deep late-stage pipeline—still ...

Noetik CEO and co-founder Ron Alfa, M.D., Ph.D., said the licensing of human foundation models is “a new paradigm in biotech.” With the GSK deal validating the paradigm, in Alfa’s view, Noetik ...

GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.

Though specific data for bepirovirsen remain under wraps, GSK plans to file for approval in the first quarter of 2026.

GSK will use promising results from two studies of its experimental chronic hepatitis B therapy to support planned regulatory ...

GSK’s potential “functional cure” for hepatitis B drug has proven its worth in a pair of hotly anticipated phase 3 studies, setting up the pharma for a push to the FDA.

The local carpenters’ union purchased the South Philadelphia office building in the Navy Yard for $52 million.

GSK announced in January that its novel chronic hepatitis B (CHB) successfully met primary goals in two pivotal phase 3 ...

GSK noted recent deals as source of fresh revenues amid patent expiries and an AI-driven boost to drug discovery.

The outgoing boss of GSK has hailed the US as the best place for pharmaceuticals firms to invest, amid fears for the future of the UK industry. GSK and UK-headquartered rival AstraZeneca have revealed ...

Emma Walmsley’s praise for US pharmaceutical market piles pressure on UK government Business live – live updates The chief executive of GSK has declared that the US is the best place for ...